Obesity Medical Services in China

Obesity is a chronic, relapsing, multifactorial disease characterized by excessive accumulation of body fat that impairs health and increases the risk of comorbidities. Defined clinically as a body mass index (BMI) ≥30 kg/m² in adults, obesity is not merely a cosmetic concern but a systemic endocrine disorder involving dysregulation of appetite control, energy homeostasis, adipokine secretion, insulin sensitivity, and neurohormonal signaling—particularly within the hypothalamus–pituitary–adipose axis. Pathogenesis involves complex interactions among genetic susceptibility (e.g., variants in FTO, MC4R), epigenetic modifications, gut microbiota dysbiosis, environmental drivers (ultra-processed food abundance, sedentary behavior, sleep deprivation, endocrine-disrupting chemicals), and psychosocial factors (chronic stress, depression, food addiction). Globally, obesity prevalence has nearly tripled since 1975: WHO estimates over 650 million adults (13% of the world’s adult population) were obese in 2022, with China reporting a national adult obesity rate of ~16.4% (2023 China Chronic Disease and Risk Factor Surveillance), rising sharply among urban youth and aging populations. Key modifiable risk factors include low physical activity (<150 min/week moderate-intensity exercise), high intake of added sugars and saturated fats, prolonged screen time, shift work, and socioeconomic disadvantage; non-modifiable risks include family history, certain genetic syndromes (e.g., Prader–Willi), and early-life factors (maternal obesity, rapid infant weight gain). Obesity profoundly diminishes quality of life—contributing to mobility limitations, chronic pain (especially knee osteoarthritis), obstructive sleep apnea, social stigma, workplace discrimination, anxiety and depression, reduced sexual function, and diminished self-efficacy. It is a leading preventable cause of type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease (NAFLD), certain cancers (endometrial, colorectal, postmenopausal breast), and all-cause mortality. Endocrinologists play a central role in diagnosing obesity as a disease—not a lifestyle failure—and managing it through comprehensive, person-centered care that integrates behavioral therapy, pharmacotherapy (e.g., GLP-1 receptor agonists like semaglutide), metabolic surgery evaluation, and longitudinal monitoring of cardiometabolic biomarkers. Early intervention significantly improves long-term outcomes, underscoring the importance of routine BMI screening, waist circumference measurement, and personalized risk stratification in primary and specialty endocrine practice.

Obesity is a chronic, relapsing, multifactorial disease characterized by excessive adipose tissue accumulation that impairs health and increases the risk of cardiovascular disease, type 2 diabetes mellitus (T2DM), obstructive sleep apnea, osteoarthritis, nonalcoholic fatty liver disease (NAFLD), and multiple malignancies. In the Department of Endocrinology, obesity management follows an evidence-based, patient-centered, staged approach aligned with international guidelines (e.g., ADA, EASO, AACE) and adapted to China’s epidemiological and healthcare context.

Conservative treatment remains the cornerstone of obesity management and should be initiated for all patients, regardless of BMI category or comorbidity burden. It comprises three interdependent pillars: medical nutrition therapy (MNT), structured physical activity, and behavioral interventions. MNT emphasizes energy deficit (typically 500–750 kcal/day reduction), high-protein (1.2–1.5 g/kg ideal body weight/day), moderate-carbohydrate (45–55% of total calories), low-glycemic-index diets rich in fiber and unsaturated fats. Meal timing strategies—including time-restricted eating (e.g., 12- to 14-hour overnight fast)—are increasingly supported by metabolic data. Physical activity prescriptions target ≥150 minutes/week of moderate-intensity aerobic exercise (e.g., brisk walking, cycling) plus two weekly sessions of resistance training to preserve lean mass and improve insulin sensitivity. Behavioral interventions—delivered via individual counseling, group programs, or digital therapeutics—focus on self-monitoring (food/activity logs), stimulus control, cognitive restructuring, goal setting, and relapse prevention. In China, culturally tailored adaptations include integration of traditional dietary patterns (e.g., emphasis on vegetables, legumes, whole grains; reduced refined carbohydrates and cooking oil), promotion of tai chi and qigong as sustainable low-impact modalities, and family-involved education given the strong influence of household eating habits.

Pharmacotherapy is indicated for adults with BMI ≥30 kg/m² or ≥25 kg/m² with at least one obesity-related comorbidity (e.g., hypertension, dyslipidemia, T2DM, NAFLD) who have not achieved ≥5% weight loss after 3–6 months of intensive lifestyle intervention. First-line agents in China include GLP-1 receptor agonists (GLP-1 RAs): semaglutide (2.4 mg subcutaneous weekly) and tirzepatide (a dual GIP/GLP-1 RA, recently approved). These agents promote satiety, delay gastric emptying, and enhance glucose-dependent insulin secretion, yielding mean weight losses of 15–22% over 68 weeks in pivotal trials. Liraglutide (3.0 mg daily) remains widely used, particularly where cost constraints exist. Orlistat (120 mg three times daily) inhibits pancreatic and gastric lipases, reducing fat absorption by ~30%; it is accessible and reimbursed under China’s National Reimbursement Drug List (NRDL), though gastrointestinal side effects limit adherence. Emerging agents—such as retatrutide (triple agonist) and cagrilintide (amylin analog)—are under clinical evaluation in Chinese Phase III trials. All pharmacotherapies require ongoing monitoring of efficacy (weight trajectory, waist circumference, HbA1c, liver enzymes), safety (pancreatitis, gallstones, psychiatric symptoms), and renal function. Contraindications include personal/family history of medullary thyroid carcinoma or MEN2 syndrome for GLP-1 RAs.

Bariatric-metabolic surgery is recommended for adults with BMI ≥37.5 kg/m² or ≥32.5 kg/m² with significant comorbidities refractory to medical therapy. Common procedures performed in Chinese endocrine centers include laparoscopic sleeve gastrectomy (LSG) and Roux-en-Y gastric bypass (RYGB). LSG—accounting for >85% of bariatric surgeries in China—is technically less complex, associated with lower perioperative morbidity, and achieves 25–35% total body weight loss (TBWL) at 2 years, with durable remission of T2DM (>60%), hypertension (>50%), and obstructive sleep apnea (>75%). RYGB offers superior glycemic control and greater weight loss but carries higher nutritional risks (e.g., iron, B12, calcium deficiency) requiring lifelong supplementation and surveillance. Endoscopic bariatric therapies—including intragastric balloon (6-month placement) and endoscopic sleeve gastroplasty (ESG)—serve as bridge options for high-risk surgical candidates or those seeking minimally invasive alternatives; ESG yields ~15–20% TBWL at 12 months with favorable safety profiles. All surgical candidates undergo comprehensive preoperative assessment: psychological evaluation, nutritional status (vitamin D, ferritin, albumin), cardiopulmonary testing, and multidisciplinary review involving endocrinology, surgery, nutrition, and psychiatry.

Treatment advantages in China stem from integrated care models, rapid adoption of novel therapeutics, and robust public health infrastructure. The National Health Commission’s ‘Healthy China 2030’ initiative prioritizes obesity prevention through school-based nutrition policies, urban green space expansion, and workplace wellness programs. Endocrinology departments in tier-1 hospitals (e.g., Peking Union Medical College Hospital, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital) operate dedicated Obesity Management Centers offering longitudinal, team-based care with standardized protocols, electronic health record–integrated decision support, and telehealth follow-up. China’s regulatory pathway enables faster approval of innovative agents—semaglutide and tirzepatide gained NMPA approval within 12 months of FDA clearance—and broad NRDL coverage improves affordability. Moreover, large-scale real-world evidence studies (e.g., the China Obesity Cohort) inform local practice guidelines and optimize risk stratification using region-specific cutoffs (e.g., BMI ≥24 kg/m² for overweight, ≥28 kg/m² for obesity in Asian populations).

Post-treatment recovery requires lifelong commitment. Patients undergoing lifestyle intervention should schedule quarterly visits for anthropometric reassessment, metabolic panel review, and motivational interviewing. Those on pharmacotherapy need monthly evaluations during dose escalation, then biannual assessments once stable. Surgical patients require mandatory follow-up at 1, 3, 6, and 12 months postoperatively, then annually: monitoring includes micronutrient panels, bone density (DEXA) every 2 years, and screening for dumping syndrome or weight regain. Nutritional rehabilitation emphasizes protein-first meals, vitamin/mineral supplementation (e.g., multivitamin with iron, B12, calcium, vitamin D), and avoidance of liquid calories and high-sugar foods. Psychological support—including cognitive-behavioral therapy and peer support groups—is critical to sustain behavior change and address emotional eating. Long-term success correlates strongly with consistent self-monitoring, social accountability, and early re-engagement upon weight plateau or regain. In summary, optimal obesity management in endocrinology demands a continuum of care—from prevention and conservative strategies to advanced pharmacotherapy and surgery—delivered with cultural competence, technological enablement, and unwavering patient partnership.